Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells.

IL-2-activated killer lymphocytes (LAK cells) secrete inflammatory cytokines such as interferon-gamma (IFN-gamma) and tumor necrosis factor alpha (TNFalpha) that can induce nitric oxide (NO) synthesis. We evaluated whether LAK cells could activate NO synthesis in human cancer cells. LAK cells and their culture supernatants induced NO synthesis in DLD-1 colon cancer cells in a dose-dependent manner. NO synthesis was inhibited completely by blocking antibodies to IFN-gamma, demonstrating a key role for this LAK cell cytokine in regulating NO synthesis. The addition of TNFalpha antibodies resulted in partial inhibition. Induction of iNOS mRNA and protein expression in DLD-1 cells was detected. Endogenous NO production inhibited DLD-1 cell proliferation and induced apoptosis, processes that were inhibitable by the NO synthase inhibitor N(G)-monomethyl-l-arginine. Our study has identified a novel, non-contact-dependent LAK cell cytotoxic mechanism: induction of growth inhibition and programmed cell death due to endogenous NO synthesis in susceptible human cancer cells.

[1]  M. Zeng,et al.  Fas-induced caspase denitrosylation. , 1999, Science.

[2]  R. Dummer,et al.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Moyer,et al.  Cytotoxic T Lymphocyte-assisted Suicide , 1998, The Journal of Biological Chemistry.

[4]  H. Fujiwara,et al.  Expression of an inducible type of nitric oxide (NO) synthase in the thymus and involvement of NO in deletion of TCR-stimulated double-positive thymocytes. , 1997, Journal of immunology.

[5]  S. Moncada.  The biology of nitric oxide , 1997 .

[6]  B. Brüne,et al.  Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. , 1996, The Biochemical journal.

[7]  A. Gow,et al.  Effects of peroxynitrite‐induced protein modifications on tyrosine phosphorylation and degradation , 1996, FEBS letters.

[8]  K. Hellstrand,et al.  Apoptotic death of human leukemic cells induced by vascular cells expressing nitric oxide synthase in response to gamma-interferon and tumor necrosis factor-alpha. , 1996, Cancer research.

[9]  S. Lippman,et al.  Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. , 1995, Cancer research.

[10]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human breast cancer. , 1995, British Journal of Cancer.

[11]  J. Stamler,et al.  Redox signaling: Nitrosylation and related target interactions of nitric oxide , 1994, Cell.

[12]  J. Balibrea,et al.  Nitrite/ nitrate and cytokine levels in bronchoalvelar lavage fluid of lung cancer patients , 1994, Cancer.

[13]  J. Albina,et al.  Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. , 1994, Cancer research.

[14]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[15]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human gynecological cancer. , 1994, Cancer research.

[16]  C. Lowenstein,et al.  Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.

[17]  S. Rosenberg,et al.  Important advances in oncology 1986 , 1994 .

[18]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[19]  W. Samlowski,et al.  Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. , 1993, Cancer research.

[20]  V. Laubach,et al.  Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line. , 1993, Biochemistry.

[21]  J. Lancaster,et al.  Induction of nitric oxide synthesis and its reactions in cultured human and rat hepatocytes stimulated with cytokines plus LPS. , 1993, Biochemical and biophysical research communications.

[22]  J. Albina,et al.  Nitric oxide-mediated apoptosis in murine peritoneal macrophages. , 1993, Journal of immunology.

[23]  E. Werner,et al.  Ca2+/calmodulin-dependent nitric oxide synthase activity in the human cervix carcinoma cell line ME-180. , 1993, The Biochemical journal.

[24]  P. Golstein,et al.  Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity , 1993, The Journal of experimental medicine.

[25]  S. Tannenbaum,et al.  DNA damage and mutation in human cells exposed to nitric oxide in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Kablitz,et al.  Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. , 1992, The Journal of clinical investigation.

[27]  V. Devita,et al.  Biologic Therapy of Cancer , 1992 .

[28]  S. Moncada,et al.  Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. , 1991, Cancer research.

[29]  C. Nathan,et al.  Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide , 1991, The Journal of experimental medicine.

[30]  E. Jaffe,et al.  Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. , 1991, Biochemical and biophysical research communications.

[31]  F. Murad,et al.  Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in N1E-115 neuroblastoma cells requires calcium and calmodulin. , 1990, Molecular pharmacology.

[32]  J. Lancaster,et al.  EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Brüne,et al.  Activation of a cytosolic ADP-ribosyltransferase by nitric oxide-generating agents. , 1989, The Journal of biological chemistry.

[34]  C. Nathan,et al.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells , 1989, The Journal of experimental medicine.

[35]  A. Ghosh,et al.  Lack of correlation between peripheral blood lymphokine‐activated killer (lak) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2 , 1989, International journal of cancer.

[36]  S. Rosenberg,et al.  IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. , 1989, Journal of immunology.

[37]  J. Hibbs,et al.  Nitric oxide: a cytotoxic activated macrophage effector molecule. , 1988, Biochemical and biophysical research communications.

[38]  R. Fisher,et al.  Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. , 1988, Cancer research.

[39]  T. Espevik,et al.  Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. , 1988, Cancer research.

[40]  J. Mier,et al.  Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. , 1988, Cancer research.

[41]  J. Hibbs,et al.  SHORT COMMUNICATION: Cytokines Induce an L‐Arginine‐Dependent Effector System in Nonmacrophage Cells , 1988, Journal of leukocyte biology.

[42]  J. Drapier,et al.  Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. , 1988, Journal of immunology.

[43]  L. Lanier,et al.  In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Jaffe,et al.  The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. , 1987, The American journal of pathology.

[45]  J. Hibbs,et al.  Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. , 1987, Science.

[46]  J. Hibbs,et al.  L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. , 1987, Journal of immunology.

[47]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[48]  J. Drapier,et al.  Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulfur prosthetic group and is reversible. , 1986, The Journal of clinical investigation.

[49]  S. Rosenberg,et al.  Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. , 1986, Cancer research.

[50]  C. Balch,et al.  Lysis of human solid tumor cells by lymphokine-activated natural killer cells. , 1986, Journal of immunology.

[51]  S. Rosenberg,et al.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. , 1986, Journal of immunology.

[52]  S. Rosenberg,et al.  Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. , 1985, Journal of immunology.

[53]  E. Grimm,et al.  The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. , 1985, Cellular immunology.

[54]  S. Rosenberg,et al.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.

[55]  S. Rosenberg,et al.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. , 1985, Journal of immunology.

[56]  L. Muul,et al.  THE DIFFERENTIAL INHIBITORY EFFECTS EXERTED BY CYCLOSPORINE AND HYDROCORTISONE ON THE ACTIVATION OF HUMAN CYTOTOXIC LYMPHOCYTES BY RECOMBINANT INTERLEUKIN‐2 VERSUS ALLOSPECIFIC CTL , 1985, Transplantation.

[57]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[58]  J. Hibbs,et al.  Iron depletion: possible cause of tumor cell cytotoxicity induced by activated macrophages. , 1984, Biochemical and biophysical research communications.

[59]  A. Lehninger,et al.  Sites of inhibition of mitochondrial electron transport in macrophage- injured neoplastic cells , 1982, The Journal of cell biology.

[60]  R. Kiessling,et al.  “Anomalous” THY-1(+) killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes , 1982, The Journal of experimental medicine.

[61]  S. Rosenberg,et al.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. , 1981, Cancer research.

[62]  D. Mathisen,et al.  The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. , 1980, Journal of immunology.

[63]  H. Borberg,et al.  Phytohemagglutinin: Inhibition of the Agglutinating Activity by N-Acetyl-d-Galactosamine , 1966, Science.

[64]  James B. Mitchell,et al.  Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. , 1996, Current topics in cellular regulation.

[65]  J. Beckman,et al.  The role of peroxynitrite in nitric oxide-mediated toxicity. , 1995, Current topics in microbiology and immunology.

[66]  E. Podack.  Perforin: structure, function, and regulation. , 1992, Current topics in microbiology and immunology.

[67]  C. Nathan,et al.  Role of nitric oxide synthesis in macrophage antimicrobial activity. , 1991, Current opinion in immunology.

[68]  J. Lancaster,et al.  Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: A molecular mechanism regulating cellular proliferation that targets intracellular iron , 1990 .

[69]  F. Bach,et al.  Continuous infusion of recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies. , 1989, Medical and pediatric oncology.

[70]  Craig W. Reynolds,et al.  Mechanism of cytotoxicity by natural killer (NK) cells. , 1986, Annual review of immunology.